Highlights from our first expression of interest review round

News
Fri Dec 20 2024
5 min read

Learn about the innovative research and diverse applications we received from around the globe.

In November 2024, we closed applications for our inaugural review round. The response was remarkable, with our triage and diligence team receiving a significant number of applications, reflecting the potential of the collaborative approach to drive progress for young patients. 

Below, we share some key highlights from this first round. We are also pleased to announce the deadline for the second round of applications: 2 March 2025.

Our first round in numbers

We received a remarkable response, with applications from both industry and academia.

 

9

Icon molecule

modalities  

Over  

10

Indications icon

indications  

Applications from  

12

Countries/international icon

countries  

The quality, quantity, and diversity of applications—spanning stages, modalities, and indications—aligns with our hopes for C-Further. This also underscores the importance of a collaborative approach in accelerating the discovery and delivery of transformative treatments for children and young people.

Sheena Patel

Principal Scientist at Cancer Research Horizons, Triage & diligence workstream